Chaitali Nangia, MD, Patty and George Hoag Cancer Center

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.